Scilex Holding (SCLX) Non Operating Investment Income (2025)
Scilex Holding (SCLX) posted quarterly Non Operating Investment Income of -$5.6 million for Q4 2025, down 167.5% on a QoQ basis from $8.3 million in Q3 2025.
Scilex Holding (SCLX) Non Operating Investment Income (2025) Analysis & Trends
Scilex Holding (SCLX) has reported Non Operating Investment Income for 1 consecutive years, with -$5.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Investment Income changed N/A year-over-year to -$5.6 million; the TTM figure through Dec 2025 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
- Non Operating Investment Income came in at -$5.6 million for Q4 2025 at Scilex Holding, down from $8.3 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $8.3 million in Q3 2025, with the low at -$5.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.59 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Sep 30, 2025 | 8.28 Mn |